Jonathan Chu

This study identifies RAC1 as a druggable target in Shh-dependent medulloblastoma by showing its role in regulating GLI1 and GLI2 transcription and demonstrating the efficacy of the inhibitor GYS32661 in reducing tumor growth.

This paper develops DrugSeq, a computational platform that predicts drug sensitivities in medulloblastoma subgroups, identifying subgroup-specific therapies and potential drug repositioning candidates.